Printer Friendly

Short-term effects of stored homologous red blood cell transfusion on cardiorespiratory function and inflammation: an experimental study in a hypovolemia model.

Introduction

Blood transfusion is an established treatment for several life-threatening conditions during critical illness. Apart from life-threatening scenarios, however, there is controversy on when to transfuse a hemodynamically stable critically ill patient. Possible adverse events of transfusion include induction of inflammatory response and pulmonary dysfunction (1-3).

In addition, long-term preservation of red blood cells (RBC) under blood bank conditions may result in the accumulation of inflammatory mediators in the storage medium and increased levels of free hemoglobin, which can scavenge nitric oxide (NO). These changes could be related to occurrence of microvascular vasoconstriction, platelet activation, and pro-inflammatory and pro-oxidant activity described in transfused patients (4).

Some clinical studies have found an association of blood transfusion with organ failure, longer hospitalizations and increased mortality (5-9). However, other studies did not find the same association (10-12). An important limitation of these data is their observational study design with the unavoidable potential for bias and residual confounding (13-15). These biases may come from the disease severity of the patients included in trials and the presence of frequent comorbidities such as sepsis and trauma. Despite the use of statistical techniques that may adjust for these and other potential confounders, it is very difficult to establish the independent role of transfusion in adverse outcomes in these settings (15). On the other hand, clinical studies to test blood transfusion effects in healthy people would be ethically unacceptable.

Complications involving the respiratory system are described as important causes of transfusion-related morbidity (16). In newborns, transfusion induced a reduction of respiratory system compliance and an increase in pulmonary vascular resistance (17). In addition, in mechanically ventilated premature infants, blood transfusion increased the concentrations of malondialdehyde (a marker of oxidative stress) on bronchoalveolar lavage (18). A study done to evaluate the increase in oxygen consumption after RBC transfusion in septic patients also showed significant increases in respiratory system resistance when compared to albumin infusion (19). In a recent study in intensive care patients on mechanical ventilation, a RBC transfusion of one unit did not induce differences in lung function, as well as in the inflammatory and coagulation status after 2 h (20). Therefore, the results are unclear and may be caused by different clinical scenarios, presence of comorbidities, variable number of transfused units and storage time.

In this context, animal studies may partially overcome these limitations, since healthy animals can be evaluated to identify possible harmful mechanisms of transfusion. The swine model has been extensively tested in critical care since there are clear similarities between these animals and human beings mainly regarding cardiopulmonary function (15,21,22). In this study, we evaluated the effect of transfusion on an experimental model without any other clinically significant insult than RBC administration, with the purpose of assessing the independent effect of blood products. We, therefore, developed a clinically relevant experimental model of RBC transfusion and we examined the immediate impact of this strategy on hemodynamics, microcirculation, pulmonary function and systemic and pulmonary inflammation.

Material and Methods

This study was approved by the Institutional Animal Research Ethics Committee from Hospital Sirio-Libanes and was performed according to the National Institute of Health Guidelines for the use of experimental animals.

Instrumentation and stabilization period

Sixteen domestic Agroceres[R] male pigs (body weight, 68 [+ or -]3.3 kg) were fasted overnight with free access to water and pre-medicated with an intramuscular injection of midazolam (0.3 mg/kg) and acepromazine (0.5 mg/kg). Anesthesia was induced with thionembutal (12 mg/kg) and muscular relaxation with pancuronium bromide (0.1 mg/kg). The animals were submitted to endotracheal intubation and mechanical ventilation (Evita XL, Drager, Germany) with the following baseline ventilatory settings: tidal volume (VT): 8 mL/kg, positive end-expiratory pressure (PEEP) of 5 cm[H.sub.2]O, peak airway flow of 1 L/s, inspiratory fraction of oxygen adjusted to maintain arterial saturation between 93-95% and respiratory rate necessary to maintain PaC[O.sub.2] between 35 and 45 mmHg. Anesthesia was maintained during the study with midazolam (0.3 mg x [kg.sup.-1] x [h.sup.-1]) and fentanyl citrate (5 [micro]g x [kg.sup.-1] x [h.sup.-1]), and muscular relaxation was maintained with pancuronium bromide (0.2 mg x [kg.sup.-1] x [h.sup.-1]). The adequate depth of anesthesia during surgery was evaluated with maintenance of physiological variables (heart rate and arterial pressure) and absence of reflexes (corneal and hind limb flexion response), as well as unresponsiveness to stimuli during manipulation. Supplementary boluses of 5 [micro]g/kg fentanyl and 0.125 mg/kg midazolam were administered as necessary.

Immediately before handling and thereafter every 6 h, all the animals received one gram of cephalothin IV as antimicrobial prophylaxis. The right external jugular vein was dissected for introduction of a pulmonary artery catheter, which was guided to the pulmonary artery by visualization of the pressure curves. A double-lumen catheter (12F) was inserted in the left jugular vein for fluid and drug administration and to collect blood during the hemorrhage period. A 5F catheter (PV2015L20, Pulsion Medical Systems, Germany) was inserted into the right femoral artery for thermodilution measurements and pulse contour analysis and connected to the Infinity[R] PiCCO SmartPod[TM] XL monitor (Infinity Delta XL, Drager).

Through a midline laparotomy, a cistostomy was performed, and a vesical catheter inserted. A Laser Doppler-Flowmetry catheter (Transonic Systems Inc., USA) was inserted in the terminal ileum to measure intestinal microcirculatory perfusion and the laparotomy was closed. After instrumentation, the animals were allowed to stabilize without interventions for 1 h and a continuous infusion of 5 mL x [kg.sup.-1] x [h.sup.-1] of lactated Ringer's solution was maintained throughout the experiment.

Systemic pressures were measured with quartz transducers (Edwards Critical Care, USA) and displayed continuously on a multi-modular monitor (Infinity Delta XL, Drager), which also measured heart rate, oxygen saturation and end-tidal C[O.sub.2]. Continuous central venous oximetry was measured by spectrophotometry and continuous cardiac output was measured by thermodilution (Vigilance[TM], Edwards, USA).

Blood collection and processing

Immediately after the stabilization period, the animals were submitted to a controlled hemorrhage of 25% of the blood volume [estimated as body weight (kg) x 70 mL) during 40 min (23). The blood was collected into citratephosphate-dextrose-adenine 1 (CPDA-1) blood bags (Fresenius Hemo Care, Brazil). The whole blood was centrifuged at 1130 g for 16 min at 4[degrees]C (Beckman-Spinchron 15 centrifuge, Beckman Coulter, USA) and separated into plasma and red blood cell using a manual Fenwal plasma extractor (Baxter, USA). In total, two RBC and two plasma units were obtained from each animal. The plasma units were discarded and the RBC units stored at 4[degrees]-8[degrees]C for 14 days. The target temperature was tracked by a temperature recorder (iButton DS1921g, USA).

After 30 min of hemorrhage and before fluid infusion, the animals were allocated in two groups: a) Control group (n=8)--fluid replacement using lactated Ringer's solution equivalent to 3 times the removed volume in up to 2 h; b) Transfusion group (n=8)--infusion of two packed RBC units (collected from another animal 14 days before) in a period of 2 h and lactated Ringer's solution in a volume correspondent to 3 times the difference between removed volume and transfused volume. RBC units were cross-matched using a visual agglutination test and were obtained from a single porcine donor. After fluid resuscitation, the animals were observed for 6 h and, at the end of the experiments, were sacrificed with potassium chloride overdose after deepening of anesthesia.

We demonstrated in a previous study that swine RBC stored under human standard conditions for 14 days had conserved viability as evaluated in vitro using free hemoglobin and hemolysis index and in vivo using RBC labeled with sodium chromate (24). The 14-day storage time was chosen based on previous studies, which demonstrated that the potential half-life of transfused swine RBC labeled with radioactive sodium chromate ranges from 14 to 20 days (25).

Hemodynamic and respiratory variables acquisition

The hemodynamic parameters measured during every condition were mean arterial blood pressure, central venous pressure, pulmonary artery pressure, heart rate, continuous central venous oximetry, cardiac output, stroke volume variation, global ventricle ejection fraction, global end diastolic volume and extravascular lung water index. Respiratory variables acquired were expired minute volume, tidal volume, respiratory rate, peak and plateau (calculated as the mean of 5 consecutive respiratory cycle plateau pressure measurements with a static inspiratory pause of 2 s) pressures, PEEP, end-tidal carbon dioxide concentration, inspiratory oxygen fraction and arterial oxygen saturation.

Pressure x volume (PV) curves of the respiratory system were done at baseline, immediately after resuscitation and after 3 and 6 h of fluid replacement, through a low flow method available in the mechanical ventilator, as described (26). The inspiratory and expiratory work estimated as the areas under the inspiratory and expiratory limbs of the PV curve were also analyzed. The difference between expiratory and inspiratory work was considered as the energy spent with lung hysteresis. All areas were normalized to the area of the smallest rectangle capable of enclosing the whole PV curve (27,28). The area of this rectangle was considered as the potential energy of the pulmonary envelope, and normalization was necessary due to the heterogeneity of viscoelastic properties of the respiratory system of the animals (29).

Laboratory analysis

Arterial samples were collected before and after the conditions described above for measurement of blood gases and arterial lactate on a blood gas analyzer (ABL 700 Radiometer, Denmark). Venous oximetry was calibrated in vivo with gas analysis of a mixed venous sample.

Inflammatory response

Before the induction of hypovolemia, and after 3 and 6 h of resuscitation, blood samples were withdrawn from arterial catheters for measurement of interleukin (IL)-6, IL-10, IL-1, and IL-21 concentrations, using porcine-specific ELISA kits for IL-6, IL10, IL-1 and a non-specific kit for IL-21, according to the manufacturer's instructions (R&D Systems, USA). We also evaluated plasma nitrate concentrations by chemiluminescence technique (Sievers NO analyzer model 280; Sievers Instruments Inc., USA) at the same time-points. The lung was collected and frozen immediately after sacrifice for the preparation of tissue homogenates (26) and pulmonary concentrations of the same cytokines and nitrate were measured using these techniques. The results were normalized for pulmonary protein concentration.

The evaluation of gene expression for several inflammatory mediators in the pulmonary tissue was carried out through reverse transcription quantitative polymerase chain reaction (RT-qPCR). For these experiments, fragments of frozen pulmonary tissue were homogenized; total RNA was isolated using the "RNAeasy Minikit" (QIAGEN Sciences, USA) following manufacturer's instructions. After cDNA synthesis from 1 [micro]g of RNA with the "SuperScript III First-Strand Synthesis Systems" (Life Technologies, USA) the cDNA samples were submitted to qPCR in the SDS7900HT (Life Technologies). GAPDH and HPRT1 were used as control genes. The probes and primers for each of the genes evaluated are as follows: IL-1[beta], sense: GGTTTCT GAAGCAGCCATGG, antisense: GATTTGCAGCTGGATG CTCC, Probe 5'(FAM)-AAAGAGATGAAGTGCTGCACC CAAAACCTG-(TAMRA)3'; IL-10, sense: TTGGAGCTTG CTAAAGGCACT, antisense: CGGCGCTGTCATCAATTT CT, Probe 50(FAM)-CACCTCCTCCACGGCCTTGCTCTT-(TAMRA)30; IL-21, Ss03384710_u1; iNOS Ss03374608_u1; TNF alpha Ss03391318_g1; HPRT-1 Ss03388274_m1; GAPDH Ss03375629_u1 (Life Technologies).

Statistical analysis

Respiratory system compliance was our primary end-point. Unlike other cardiovascular and inflammatory parameters, previous clinical (17) and experimental (15) studies have demonstrated alterations on this variable after stored RBC transfusion. Based on our previous experimental work that measured this variable, we estimated that a study with 16 animals (8 animals per group) would have an 80% power to detect a difference of 25% in respiratory system compliance between groups, considering a normal value of 35 mL/mmHg and a within-group standard deviation of 5 mL/mmHg (29).

Data were tested for normality using Shapiro-Wilk test and are reported as means [+ or -] SD or median (p25-p75) according to their distribution. Evolutive data (hemodynamic, oxygenation, respiratory) are reported as mean and SD over time and were compared using two-way analysis of variance (ANOVA). Bonferroni correction for multiple comparisons was used, and for five-time point comparisons (baseline, hemorrhage, immediate resuscitation, 3 and 6 h), significance was considered when P [less than or equal to] 0.01 for the three levels of the analysis (between, within, and factor x time interaction). Post-hoc analyses were performed with the Tukey test. Non-parametric data were evaluated with the Friedman test and Tukey post-hoc analysis. The commercially available SigmaStat 2.0 statistical package (Systat Software, USA) was used.

Results

As expected, hypovolemia was associated to significant reductions in mean arterial pressure, cardiac output, mixed venous oxygen saturation (Figure 1A, B and C) in both groups. In addition, hypovolemia significantly increased stroke volume variation (Figure 1D). In both groups, fluids and RBC transfusion partially or fully reestablished these parameters. However, the transfused group had higher values of central venous oxygen saturation (Figure 1C) and arterial oxygen content (Figure 2A). There was a significant increase in hemoglobin and hematocrit level (Table 1) of the transfused group compared to the control animals. Transfusion did not influence the microcirculation and perfusion as assessed by Laser Doppler flowmetry (Figure 2B) and lactate concentrations (Table 1).

Table 2 demonstrates the effects of RBC transfusion on respiratory function. We were unable to identify any acute effect of transfusion in the several variables evaluated. Importantly, transfusion did not induce a significant effect on extravascular thermal volume index, which is a surrogate for extravascular lung water (30). There was a significant increase in the energy spent on inspiratory work and pulmonary hysteresis for the control group (Table 2). This may be representative of increased cumulative fluid balance in the control group (Table 1). Transfusion perse did not cause significant alterations in these variables.

The plasma concentrations of the several evaluated cytokines before and after fluid replacement and RBC transfusion were below the ELISA detection threshold for the vast majority of animals studied (data not shown). In Figure 3A-D, cytokine concentrations in the lung tissue are reported. There was no difference between transfused and non-transfused groups. A small although statistically significant difference between transfused and control groups was obtained for relative mRNA quantitation of NOS2 and IL-21, with a two-fold increase in the former and a 50% decrease in the latter in the transfused animals compared to controls (Figure 3E). Plasma and pulmonary concentrations of nitrate are reported in Figure 4 and no significant differences were observed between groups.

Discussion

In this study, we describe a swine experimental model of stored homologous RBC transfusion that may be used to study the clinical and mechanistic effects of this strategy commonly used in clinical practice. In addition, we demonstrate that stored RBC transfusion is not related to acute clinically significant effects on pulmonary function, microcirculation and lung inflammation in otherwise normal animals.

The association between pulmonary complications and RBC transfusion is described mainly in observational studies. An early trial done in anemic preterm infants demonstrated that transfusion induced a reduction in respiratory compliance, increments in pulmonary vascular resistance and increased work of breathing. However, these alterations may not be the result of transfusion per se but may have occurred due to either volume overload or increases in lung water content (17). These deleterious effects were not reproduced in other studies, since transfusion decreased the work of breathing without any harmful effect on gas exchange in both patients with chronic obstructive pulmonary disease and in anemic controls (31). A study in patients undergoing cardiopulmonary bypass did not identify significant alterations in gas exchange in those with multiple transfusions, compared to few transfusions or non-transfused patients (32). Another study in cardiothoracic surgery patients showed a dose-dependent increase in pulmonary capillary permeability (33). Additionally, a study in healthy volunteers demonstrated subclinical acute pulmonary alterations one hour after autologous RBC transfusion evidenced by impaired oxygen gas exchange, however without any significant effect in arterial oxygen pressure (34).

In the present report, we did not find any clinically significant effect of RBC administration on gas exchange and respiratory mechanics thus suggesting that this strategy of transfusion does not induce acute respiratory derangement in normal lungs.

Few studies in the literature assessed the effects of RBC transfusion on inflammatory response, with discordant results. In normal rats, blood transfusion did not induce lung inflammation, which is similar to our results (35). However, pre-treatment with endotoxin significantly amplified the inflammatory effects of transfusion with increase in neutrophil counts and chemokine concentrations in the airways (34). A study that developed a swine model similar to ours demonstrated that transfusion of old stored RBC (mean 37 days of storage) is associated with significant decrements on renal function and augmentation of inflammatory response in a swine cardiopulmonary bypass model (15). However, these authors used a very long storage time since the half-life of homologous transfused RBC in swine is up to 20 days (25). Moreover, the RBC average life spans are shorter in pigs than in humans (86 vs 120 days) (36), which suggests that the effects observed in this study would be very difficult to reproduce in human conditions. In our study, the only significant effects of RBC transfusion on pulmonary inflammation were the modifications on pulmonary gene expression of NOS2 and IL-21. NOS2 has been consistently correlated to inflammation and IL-21 is a recently studied cytokine that interacts with IL-10 in the regulation of anti-inflammatory response (37). However, these alterations were not followed by significant changes in the downstream pathways of these mediators, since we could not identify variations in the IL-21 protein or nitrate concentration in pulmonary tissue. It is possible that the effect of RBC on lung inflammation would augment with the exposure to a concomitant insult like sepsis or lung injury or by a more extended period of observation.

Regarding clinical situations, a previous study detected increases in plasma concentrations of IL-6 and IL-8 after RBC transfusion in critically ill patients (38). In addition, a study more specifically focused on the pulmonary effects of RBC administration suggested that in patients concomitantly submitted to cardiopulmonary bypass and blood transfusion, multiple transfusions were associated with increased concentrations of cytokines and coagulation factors in the bronchoalveolar lavage (32). However, a more recent study evaluating lung function in healthy volunteers after fresh and stored autologous RBC transfusion could not find any significant changes in hemodynamic, respiratory and inflammatory variables. These results demonstrate the controversy of the theme (39).

An important discussion in the field of transfusion medicine is whether the storage lesion is associated with clinical unfavorable outcomes (40). Observational studies and experimental data have demonstrated an association between storage injury, inflammatory response and grim prognosis (4). However, clinical trials and a subsequent meta-analysis demonstrated no cause-effect relationship between transfusion of old blood and significant adverse effects or mortality, compared to flesh blood (40). Thus, this question is still unsolved. The model presented here can help to clarify the mechanisms related to storage lesion in future experiments with different blood preservation periods.

Our study has some major strengths, such as the extensive evaluation of hemodynamics, pulmonary function and the assessment of possible mechanistic pathways associated with transfusion-related lung effects. On the other hand, a limitation of our data is the possibility of type II errors in the analysis, due to a relatively small sample. Another limitation is the relatively short period of observation after blood transfusion. Deleterious effects of RBC transfusion might occur later, although previous experimental studies demonstrated that harmful effects of transfusion occurred as early as 1.5 and 4 h after RBC administration (21). Besides, we did not evaluate the effect of RBC transfusion in animals previously submitted to other injuries like sepsis, lung dysfunction or anemia or using different blood storage periods, so the clinical translation of our results is not straightforward. In previously "activated" lungs, the effects of blood transfusion might be potentiated, as discussed earlier. However, our major objective here was to evaluate the independent effects of blood transfusion in otherwise healthy lungs and to provide a feasible and consistent model of RBC transfusion that may be used in experimental studies in intensive care scenarios.

We successfully developed an experimental model of RBC transfusion in pigs that may be used to carry out mechanistic research aiming at cardiovascular and respiratory functions. Importantly, we also demonstrated that transfusion of RBC stored for 14 days was not associated with acute clinically significant cardiac, respiratory and pulmonary inflammatory effects in otherwise healthy pigs submitted to hypovolemia. Subsequent studies are required to assess the pathophysiological consequences of adding RBC transfusion to experimental models of critical illnesses.

http://dx.doi.org/10.1590/1414-431X20176258

Acknowledgments

This study was supported by grants from Research and Education Institute and from Blood Bank, Hospital Sirio-Libanes, Sao Paulo, SP, Brazil.

References

(1.) Glynn SA. The red blood cell storage lesion: a method to the madness. Transfusion 2010; 50: 1164-1169, doi: 10.1111/j.1537-2995.2010.02674.x.

(2.) Cornet AD, Zwart E, Kingma SD, Groeneveld AB. Pulmonary effects of red blood cell transfusion in critically ill, non-bleeding patients. Transfus Med 2010; 20: 221-226, doi: 10.1111/j.1365-3148.2010.01000.x.

(3.) Gong MN, Thompson BT, Williams P, Pothier L, Boyce PD, Christiani DC. Clinical predictors of and mortality in acute respiratory distress syndrome: potential role of red cell transfusion. Crit Care Med 2005; 33: 1191-1198, doi: 10.1097/01.CCM.0000165566.82925.14.

(4.) Roback JD. Perspectives on the impact of storage duration on blood quality and transfusion outcomes. Vox Sanguinis 2016 111: 357-364, doi: 10.1111/vox.12441.

(5.) Zilberberg MD, Carter C, Lefebvre P, Raut M, Vekeman F, Duh MS, et al. Red blood cell transfusions and the risk of acute respiratory distress syndrome among the critically ill: a cohort study. Crit Care 2007; 11: R63, doi: 10.1186/cc5934.

(6.) Moore FA, Moore EE, Sauaia A. Blood transfusion: an independent risk factor for postinjury multiple organ failure. Arch Surg 1997; 132: 620-625, doi: 10.1001/archsurg.1997. 01430300062013.

(7.) Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999; 340: 409-417, doi: 10.1056/NEJM199902113400601.

(8.) Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham E, et al. The CRIT Study: Anemia and blood transfusion in the critically ill - current clinical practice in the United States. Crit Care Med 2004; 32: 39-52, doi: 10.1097/01.CCM.0000104112.34142.79.

(9.) Vincent JL, Baron JF, Reinhart K, Gattinoni L, Thijs L, Webb A, et al. Anemia and blood transfusion in critically ill patients. JAMA 2002; 288: 1499-1507, doi: 10.1001/jama.288.12.1499.

(10.) Vincent JL, Sakr Y, Sprung C, Harboe S, Damas P. Are blood transfusions associated with greater mortality rates? Results of the sepsis occurrence in acutely ill patients study. Anesthesiology 2008; 108: 31-39, doi: 10.1097/01.anes. 0000296070.75956.40.

(11.) Parsons EC, Hough CL, Seymour CW, Cooke CR, Rubenfeld GD, Watkins TR. Red blood cell transfusion and outcomes in patients with acute lung injury, sepsis and shock. Crit Care 2011; 15: R221, doi: 10.1186/cc10458.

(12.) Edgren G, Kamper-Jergensen M, Eloranta S, Rostgaard K, Custer B, Ullum H, et al. Duration of red blood cell storage and survival of transfused patients. Transfusion 2010; 50: 1185-1195, doi: 10.1111/j.1537-2995.2010.02583.x.

(13.) Levy JH, Steiner ME. Transfusion Medicine and Hemostasis Clinical Trials Network Clinical studies of erythrocyte outcomes and mortality: size really counts. Anesthesiology 2013; 118: 10-12, doi: 10.1097/ALN.0b013e3182746a47.

(14.) van de Watering L. Red cell storage and prognosis. Vox Sang 2011; 100: 36-45, doi: 10.1111/j.1423-0410.2010.01441.x.

(15.) Patel NN, Lin H, Toth T, Welsh GI, Jones C, Ray P, et al. Reversal of anemia with allogenic RBC transfusion prevents post-cardiopulmonary bypass acute kidney injury in swine. Am J Physiol Renal Physiol 2011; 301: F605-F614, doi: 10.1152/ajprenal.00145.2011.

(16.) Food and Drug Administration (US). Fatalities Reported to FDA Following Blood Collection and Transfusion: Annual Summary for Fiscal Year 2012 [updated 03/28/2014]. Available at http://www.fda.gov/biologicsbloodvaccines/safety availability/reportaproblem/transfusiondonationfatalities/ucm346639.htm. Accessed February 18, 2016.

(17.) Sasidharan P, Heimler R. Alterations in pulmonary mechanics after transfusion in anemic preterm infants. Crit Care Med 1990; 18: 1360-1362, doi: 10.1097/00003246-19901200000010.

(18.) Collard KJ, Godeck S, Holley JE. Blood transfusion and pulmonary lipid peroxidation in ventilated premature babies. Pediatr Pulmonol 2005; 39: 257-261, doi: 10.1002/ppul. 20190.

(19.) Fernandes CJ Jr, Akamine N, De Marco FV, De Souza JA, Lagudis S, Knobel E. Red blood cell transfusion does not increase oxygen consumption in critically ill septic patients. Crit Care 2001; 5: 362-367, doi: 10.1186/cc1070.

(20.) Kor DJ, Kashyap R, Weiskopf RB, Wilson GA, van Buskirk CM, Winters JL, et al. fresh red blood cell transfusion and short-term pulmonary, immunologic, and coagulation status: a randomized clinical trial. Am J Respir Crit Care Med 2012; 185: 842-850, doi: 10.1164/rccm.201107-1332OC.

(21.) Patel NN, Lin H, Jones C, Walkden G, Ray P, Sleeman PA, et al. Interactions of cardiopulmonary bypass and erythrocyte transfusion in the pathogenesis of pulmonary dysfunction in Swine. Anesthesiology 2013; 119: 365-378, doi: 10.1097/ALN.0b013e31829419d3.

(22.) Azevedo LC, Park M, Noritomi DT, Maciel AT, Brunialti MK, Salomao R. Characterization of an animal model of severe sepsis associated with respiratory dysfunction. Clinics 2007, 62: 491-498, doi: 10.1590/S1807-59322007000400017.

(23.) Knotzer H, Pajk W, Maier S, Dunser MW, Ulmer H, Schwarz B, et al. Comparison of lactated Ringer's, gelatine and blood resuscitation on intestinal oxygen supply and mucosal tissue oxygen tension in haemorrhagic shock. Br J Anaesth 2006; 97: 509-516, doi: 10.1093/bja/ael208.

(24.) Biagini S, Costa PA, Wendell S, Schettino G, Azevedo LCP. In vitro and in vivo validation of stored swine erythrocyte viability to establish an experimental model of homologous red blood cell transfusion: a pilot study. Rev Bras Ter Intensiva 2014; 26: 287-291, doi: 10.5935/0103-507X.20140040.

(25.) Mulder JB, Brown RV, Corwin LA Jr. 51-chromium labeled erythrocyte half-tome disappearance from miniature swine. Can J Comp Med 1972; 36: 103-107.

(26.) Rosario AL, Park M, Brunialti MK, Mendes M, Rapozo M, Fernandes D, et al. SvO(2)-guided resuscitation for experimental septic shock: effects of fluid infusion and dobutamine on hemodynamics, inflammatory response, and cardiovascular oxidative stress. Shock 2011; 36: 604-612, doi: 10.1097/SHK.0b013e3182336aa4.

(27.) Peters RM. The energy cost (work) of breathing. Ann Thorac Surg 1969; 7: 51-67, doi: 10.1016/S0003-4975(10)66146-2.

(28.) Cabello B, Mancebo J. Work of breathing. Intensive Care Med 2006, 32: 1311-1314.

(29.) da Silva Almeida JR, Machado FS, Schettino GP, Park M, Azevedo LC. Cardiopulmonary effects of matching positive end-expiratory pressure to abdominal pressure in concomitant abdominal hypertension and acute lung injury. J Trauma 2010; 69: 375-383, doi: 10.1097/TA.0b013e3181e12b3a.

(30.) Groeneveld AB, Verheij J. Is pulmonary edema associated with a high extravascular thermal volume? Crit Care Med 2004; 32: 899-901, doi: 10.1097/01.CCM.0000115246. 59910.AB.

(31.) Schonhofer B, Wenzel M, Geibel M, Kohler D. Blood transfusion and lung function in chronically anemic patients with severe chronic obstructive pulmonary disease. Crit Care Med 1998; 26:1824-1828, doi: 10.1097/00003246199811000-00022.

(32.) Tuinman PR, Vlaar AP, Cornet AD, Hofstra JJ, Levi M, Meijers JC, et al. Blood transfusion during cardiac surgery is associated with inflammation and coagulation in the lung: a case control study. Crit Care 2011; 15: R59, doi: 10.1186/cc10032.

(33.) Vlaar AP, Cornet AD, Hofstra JJ, Porcelijn L, Beishuizen A, Kulik W, et al. The effect of blood transfusion on pulmonary permeability in cardiac surgery patients: a prospective multicenter cohort study. Transfusion 2012; 52: 82-90, doi: 10.1111/j.1537-2995.2011.03231.x.

(34.) Weiskopf RB, Feiner J, Toy P, Twiford J, Shimabukuro D, Lieberman J, et al. Fresh and stored red blood cell transfusion equivalently induce subclinical pulmonary gas exchange deficit in normal humans. Anesth Analg 2012; 114: 511-519, doi: 10.1213/ANE.0b013e318241fcd5.

(35.) Mangalmurti NS, Xiong Z, Hulver M, Ranganathan M, Liu XH, Oriss T, et al. Loss of red cell chemokine scavenging promotes transfusion-related lung inflammation. Blood 2009; 113: 1158-1166, doi: 10.1182/blood-2008-07-166264.

(36.) Eckermann JM, Buhler LH, Zhu A, Dor FJ, Awwad M, Cooper DK. Initial investigation of the potential of modified porcine RBCs for transfusion in primates. Xeno-transplantation 2004; 11: 18-26, doi: 10.1111/j.1399-3089.2004.00087.x.

(37.) Spolski R, Hyoung-Pyo K, Zhu W, Levy DE, Leonard WJ. IL-21 mediates suppressive effects via its induction of IL-10. J Immunol 2009; 182: 2859-2867, doi: 10.4049/jimmunol. 0802978.

(38.) Johnson JL, Moore EE, Gonzalez RJ, Fedel N, Partrick DA, Silliman CC. Alteration of the post injury hyperinflammatory response by means of resuscitation with a red cell substitute. J Trauma 2003; 54: 133-139, doi: 10.1097/00005373-2003 01000-00016.

(39.) Peters AL, van Hezel ME, Cortjens B, Tuip-de Boer AM, van Bruggen R, Korte D, et al. Transfusion of 35-day stored RBCs in the presence of endotoxemia does not result in lung injury in humans. Crit Care Med 2016; 44: e412-e419, doi: 10.1097/CCM.0000000000001614.

(40.) Chai-Adisaksopha C, Alexander PE, Guyatt G, Crowther MA, Heddle NM, Devereaux PJ, et al. Mortality outcomes in patients transfused with fresher versus older red blood cells: a meta-analysis. Vox Sang 2017; 112: 268-278, doi: 10.1111/vox.12495.

S. Biagini [1] *, C.S. Dale [2], J.M. Real [3,4,5], E.S. Moreira [1,6], C.R.R. Carvalho [7], G.P.P. Schettino [7,8], S. Wendel [1,9] and L.C.P. Azevedo [1,10]

[1] Instituto de Ensino e Pesquisa, Hospital Sirio-Libanes, Sao Paulo, SP, Brasil

[2] Laboratorio de Neuromodulacao e Dor Experimental, Departamento de Anatomia, Universidade de Sao Paulo, Sao Paulo, SP, Brasil

[3] Associacao TUCCA para Criancas e Adolescentes com Cancer, Departamento de Oncologia Pediatrica, Hospital Santa Marcelina, Sao Paulo, Brasil

[4] Centro de Investigacao Translacional em Oncologia, Instituto do Cancer do Estado de Sao Paulo, Universidade de Sao Paulo, Sao Paulo, SP, Brasil

[5] Hospital do Servidor Publico Estadual de Sao Paulo (IAMSPE), Sao Paulo, SP, Brasil

[6] Evidencias--Kantar Health, Sao Paulo, SP, Brasil

[7] Departamento de Cardiopneumologia, Instituto do Coracao, Universidade de Sao Paulo, Sao Paulo, SP, Brasil

[8] Hospital Municipal da Vila Santa Catarina, Sociedade Beneficente Israelita Albert Einstein, Sao Paulo, SP, Brasil

[9] Banco de Sangue, Hospital Sirio-Libanes, Sao Paulo, SP, Brasil

[10] Disciplina de Emergencias Clinicas, Universidade de Sao Paulo, Sao Paulo, SP, Brasil

Correspondence: L.C.P. Azevedo: <luciano.azevedo@hsl.org.br>

* The present address of S. Biagini is Fundacao Pro-Sangue Hemocentro de Sao Paulo, Sao Paulo, SP, Brasil.

Received February 26, 2017 | Accepted August 11, 2017

Caption: Figure 1. Sequential hemodynamic parameters of the groups during the study. Panel A, Mean systemic arterial blood pressure (ANOVA between factor P=0.156, within factor P<0.001 and factor-time interaction P=0.054). PanelB, Cardiac output (ANOVA between factor P=0.013, within factor P<0.001 and factor-time interaction P=0.773). Panel C, Mixed venous oxygen saturation (Sv[O.sub.2]) (ANOVA between factor P<0.001, within factor P<0.001 and factor-time interaction P=0.019). Panel D, Stroke volume variation (ANOVA between factor P=0.037, within factor P<0.001 and factor-time interaction P=0.207). Gray lines and markers denote all data recorded for 8 animals per group. Black markers denote the data that were chosen a priori to be analyzed. * P<0.05 vs baseline, (#) P<0.05 vs control group, ([section]) P<0.05 vs hemorrhage (post-hoc Bonferroni correction).

Caption: Figure 2. Sequential oxygenation and perfusion parameters of the groups during the study. Panel A, Arterial oxygen content (ANOVA between factor P<0.001, within factor P=0.039 and factor-time interaction P=0.015). PanelB, Arbitrary microcirculatory perfusion units (ANOVA between factor P=0.026, within factor P=0.146 and factor-time interaction P=0.841). Gray lines and markers denote all data recorded for 8 animals per group. Black markers denote the data that were chosen a priori to be analyzed. * P<0.05 vs baseline, ([section]) P<0.05 vs hemorrhage (post-hoc Bonferroni correction).

Caption: Figure 3. Inflammatory parameters of the groups during the study. Panel A, pulmonary IL-6 concentrations (P=0.401, t-test). Panel B, pulmonary IL-10 concentrations (P=0.817, t-test). Panel C, pulmonary IL-21 concentrations (P=0.567, t-test). Panel D, pulmonary IL-1 concentrations (P=0.844, t-test). Panel E, Relative mRNA quantification (RQ) for cytokines and NOS2 in lung tissue. Data are reported as means [+ or -]SD for 8 animals per group. Animals were sacrificed 6 h after the end of transfusion. * P<0.05 vs Control (t-test).

Caption: Figure 4. Nitrate concentrations of the groups during the study. Panel A, plasma nitrate concentrations of both groups (P=0.021, Friedman test). * P<0.05 vs baseline (Tukey post-hoc analysis). Panel B, pulmonary nitrate concentrations of both groups (P=0.505, Mann-Whitney rank sum test). Data are reported as medians and interquartile range for 8 animals per group. Animals were sacrificed 6 h after the end of transfusion.
Table 1. Hemodynamic and laboratory variables of the groups during
the study period.

Variable/Group                   Baseline             Hemorrhage

                                          Cardiac output

Heart rate (bpm)
  Transfusion                111 [+ or -] 16      118 [+ or -] 17
  Control                    108 [+ or -] 26      133 [+ or -] 32
Cardiac Index (mL/kg)
  Transfusion                106 [+ or -] 27       65 [+ or -] 17 *

  Control                    113 [+ or -] 28       86 [+ or -] 32
GEDVI
  Transfusion                557 [+ or -] 99      449 [+ or -] 87
  Control                    630 [+ or -] 139     507 [+ or -] 148

                                          Left ventricle

PAOP (mmHg)
  Transfusion                  8 [+ or -] 3         7 [+ or -] 4
  Control                      6 [+ or -] 2         5 [+ or -] 1
SVRI [dynes x [s.sup.-1]
  x [([cm.sup.5]).sup.-1]
  x [kg.sup.-1]]
  Transfusion                100 [+ or -] 32      110 [+ or -] 31

  Control                      89 [+ or -] 24     101 [+ or -] 33
LVSWI [(mL x mmHg) x
  [kg.sup.-1] x
  [beat.sup.-1])]
  Transfusion                1.5 [+ or -] 0.2     0.6 [+ or -] 0.2 *

  Control                    1.7 [+ or -] 0.3     0.8 [+ or -] 0.2 *

                                          Right ventricle

PAPm
  Transfusion                 25 [+ or -] 3        17 [+ or -] 6 *
  Control                     25 [+ or -] 5        19 [+ or -] 4
CVP (mmHg)
  Transfusion                  6 [+ or -] 1         5 [+ or -] 1
  Control                      5 [+ or -] 2         3 [+ or -] 2
PVRI [dynes x [s.sup.-1]                             ([section])
  x [([cm.sup.5]).sup.-1]
  x [kg.sup.-1]]
  Transfusion                 13 [+ or -] 3        12 [+ or -] 6
  Control                     13 [+ or -] 5        13 [+ or -] 6
RVSWI [(mL x mmHg) x
  [kg.sup.-1] x
  [beat.sup.-1])]
  Transfusion               0.24 [+ or -] 0.08   0.09 [+ or -] 0.06 *

  Control                   0.29 [+ or -] 0.05   0.14 [+ or -] 0.05 *

                                      Perfusion and laboratory

Urinary flow (mL/kg/h)
  Transfusion                1.6 [+ or -] 0.9     0.7 [+ or -] 0.5
                               ([section])
  Control                    3.3 [+ or -] 1.7     1.4 [+ or -] 0.9 *
Cumulative fluid balance
  (mL/kg)
  Transfusion                 20 [+ or -] 6               --

  Control                     20 [+ or -] 3               --
Lactate (mEq/L)
  Transfusion                2.0 [+ or -] 0.6     2.1 [+ or -] 0.6
  Control                    2.1 [+ or -] 0.9     2.6 [+ or -] 0.6
SBE (mEq/L)
  Transfusion                4.0 [+ or -] 3.6     1.5 [+ or -] 4.3
                                                     ([section])
  Control                    5.7 [+ or -] 1.8     4.4 [+ or -] 2.2
Hemoglobin
  Transfusion               10.7 [+ or -] 0.7     9.9 [+ or -] 0.4

  Control                   10.0 [+ or -] 0.7     9.2 [+ or -] 1.1
Hematocrit
  Transfusion                 33 [+ or -] 2        31 [+ or -] 1
                               ([section])
  Control                     27 [+ or -] 9        29 [+ or -] 3

Variable/Group                             Resuscitation

                                   1 h                   3 h

                                          Cardiac output

Heart rate (bpm)
  Transfusion                114 [+ or -] 11      119 [+ or -] 12
  Control                    130 [+ or -] 29      140 [+ or -] 31
Cardiac Index (mL/kg)
  Transfusion                 90 [+ or -] 22       97 [+ or -] 13

  Control                    111 [+ or -] 27      117 [+ or -] 24
GEDVI
  Transfusion                512 [+ or -] 60      504 [+ or -] 79
  Control                    552 [+ or -] 130     529 [+ or -] 118

                                          Left ventricle

PAOP (mmHg)
  Transfusion                  8 [+ or -] 3         8 [+ or -] 3
  Control                      8 [+ or -] 2         6 [+ or -] 2
SVRI [dynes x [s.sup.-1]
  x [([cm.sup.5]).sup.-1]
  x [kg.sup.-1]]
  Transfusion                115 [+ or -] 29       98 [+ or -] 16
                               ([section])
  Control                     87 [+ or -] 25       76 [+ or -] 18
LVSWI [(mL x mmHg) x
  [kg.sup.-1] x
  [beat.sup.-1])]
  Transfusion                1.3 [+ or -] 0.2     1.2 [+ or -] 0.1
                                   (#)                   (#)
  Control                    1.3 [+ or -] 0.4     1.2 [+ or -] 0.2 *
                                   *(#)
                                          Right ventricle

PAPm
  Transfusion                 24 [+ or -] 4        26 [+ or -] 7 (#)
  Control                     23 [+ or -] 3        26 [+ or -] 8
CVP (mmHg)
  Transfusion                  6 [+ or -] 1         6 [+ or -] 1
  Control                      4 [+ or -] 2         4 [+ or -] 2
PVRI [dynes x [s.sup.-1]                             ([section])
  x [([cm.sup.5]).sup.-1]
  x [kg.sup.-1]]
  Transfusion                 14 [+ or -] 3        15 [+ or -] 7
  Control                     11 [+ or -] 3        14 [+ or -] 8
RVSWI [(mL x mmHg) x
  [kg.sup.-1] x
  [beat.sup.-1])]
  Transfusion               0.20 [+ or -] 0.07   0.23 [+ or -] 0.09
                                   (#)                   (#)
  Control                   0.23 [+ or -] 0.06   0.24 [+ or -] 0.03
                                                         (#)

                                      Perfusion and laboratory

Urinary flow (mL/kg/h)
  Transfusion                2.3 [+ or -] 0.9     2.4 [+ or -] 1.6

  Control                    3.0 [+ or -] 2.1     2.6 [+ or -] 1.7
Cumulative fluid balance
  (mL/kg)
  Transfusion                 28 [+ or -] 7        37 [+ or -] 6
                               ([section])          *([section])
  Control                     43 [+ or -] 4 *      50 [+ or -] 8 *
Lactate (mEq/L)
  Transfusion                1.7 [+ or -] 0.5     1.3 [+ or -] 0.4
  Control                    1.7 [+ or -] 0.6     1.3 [+ or -] 0.4
SBE (mEq/L)                                              (#)
  Transfusion                3.8 [+ or -] 2.6     3.9 [+ or -] 3.2

  Control                    5.0 [+ or -] 1.7     5.6 [+ or -] 2.0
Hemoglobin
  Transfusion               10.7 [+ or -] 0.9    11.2 [+ or -] 1.1
                               ([section])               (#)
  Control                    8.1 [+ or -] 0.7 *   9.0 [+ or -] 1.1
Hematocrit
  Transfusion                  3 [+ or -] 2         3 [+ or -] 3
                               ([section])           ([section])
  Control                     25 [+ or -] 2        28 [+ or -] 3

Variable/Group                 Resuscitation            P value

                                    6 h

                                          Cardiac output

Heart rate (bpm)
  Transfusion                124 [+ or -] 13       0.10 ([paragraph])
  Control                    135 [+ or -] 23       0.019 (&)
Cardiac Index (mL/kg)
  Transfusion                 91 [+ or -] 15      <0.001 ([paragraph])
                                ([section])
  Control                    119 [+ or -] 25      <0.001 (+)
GEDVI
  Transfusion                462 [+ or -] 109      0.054 ([paragraph])
  Control                    528 [+ or -] 130      0.043 (&)

                                          Left ventricle

PAOP (mmHg)
  Transfusion                  7 [+ or -] 4        0.475 ([paragraph])
  Control                      7 [+ or -] 4        0.110 (&)
SVRI [dynes x [s.sup.-1]
  x [([cm.sup.5]).sup.-1]
  x [kg.sup.-1]]
  Transfusion                 99 [+ or -] 21       0.109 ([paragraph])
                                ([section])
  Control                     69 [+ or -] 17      <0.001 (&)
LVSWI [(mL x mmHg) x
  [kg.sup.-1] x
  [beat.sup.-1])]
  Transfusion                1.1 [+ or -] 0.2     <0.001 ([paragraph])
                                   *(#)
  Control                    1.1 [+ or -] 0.2 *    0.153 (&)

                                          Right ventricle

PAPm
  Transfusion                 27 [+ or -] 6 (#)    0.003 ([paragraph])
  Control                     22 [+ or -] 6        0.538 (&)
CVP (mmHg)
  Transfusion                  6 [+ or -] 1        0.082 ([paragraph])
  Control                      5 [+ or -] 2       <0.001 (&)
PVRI [dynes x [s.sup.-1]
  x [([cm.sup.5]).sup.-1]
  x [kg.sup.-1]]
  Transfusion                 17 [+ or -] 2        0.851 ([paragraph])
  Control                     10 [+ or -] 5        0.111 (&)
RVSWI [(mL x mmHg) x
  [kg.sup.-1] x
  [beat.sup.-1])]
  Transfusion               0.21 [+ or -] 0.09    <0.001 ([paragraph])
                                    (#)
  Control                   0.20 [+ or -] 0.04     0.084 (&)

                                      Perfusion and laboratory

Urinary flow (mL/kg/h)
  Transfusion                1.8 [+ or -] 0.8      0.006 ([paragraph])

  Control                    1.9 [+ or -] 0.9      0.027 (&)
Cumulative fluid balance
  (mL/kg)
  Transfusion                 46 [+ or -] 6       <0.001 ([paragraph])
                               *([section]+)
  Control                     59 [+ or -] 11      <0.001 (&)
Lactate (mEq/L)                    *(++)
  Transfusion                1.2 [+ or -] 0.2     <0.001 ([paragraph])
  Control                    1.3 [+ or -] 0.5      0.467 (&)
SBE (mEq/L)                         (#)
  Transfusion                4.3 [+ or -] 2.7      0.182 ([paragraph])

  Control                    6.3 [+ or -] 2.1      0.004 (&)
Hemoglobin
  Transfusion               11.4 [+ or -] 0.9      0.029 ([paragraph])
                                ([section])
  Control                    8.9 [+ or -] 1.2     <0.001 (&)
Hematocrit
  Transfusion                 35 [+ or -] 2        0.459 ([paragraph])
                                ([section])
  Control                     28 [+ or -] 4       <0.001 (&)

Data are reported as means [+ or -] SD for 8 animals per group.
GEDVI: global end diastolic volume indexed; PAOP: pulmonary artery
occlusion pressure; SVRI: systemic vascular resistance index; LVSWI:
left ventricle stroke work index; PAPm: pulmonary arterial pressure
media; CVP: central venous pressure; PVRI: pulmonary vascular
resistance index; RVSWI: right ventricle stroke work index; SBE:
standard base excess. ([paragraph]) ANOVA two-way within factor. (&)
ANOVA two-way between factor. There was no factor vs time
interaction. * P<0.05 vs baseline (Tukey's post-hoc analysis); (#)
P<0.05 vs hemorrhage (Tukey's post-hoc analysis); ([section]) P<0.05
vs control group (Tukey's post-hoc analysis); (+) P<0.05 vs 1 h
resuscitation (Tukey's post-hoc analysis).

Table 2. Respiratory parameters of the groups during
the study period.

Variable                        Baseline          Hemorrhage

P/F ratio
  Transfusion               381 [+ or -] 43    372 [+ or -] 31
  Control                   343 [+ or -] 70    332 [+ or -] 79
EtC[O.sub.2] (mmHg)
  Transfusion                34 [+ or -] 4      34 [+ or -] 5
                              ([section])
  Control                    37 [+ or -] 3      37 [+ or -] 3
Ppeak (cm[H.sub.2]O)
  Transfusion                21 [+ or -] 1      20 [+ or -] 2
  Control                    24 [+ or -] 4      23 [+ or -] 4
Pplateau (cm[H.sub.2]O)
  Transfusion                17 [+ or -] 1      16 [+ or -] 2
  Control                    17 [+ or -] 4      17 [+ or -] 4
Pmean (cm[H.sub.2]O)
  Transfusion                10 [+ or -] 0.4     9 [+ or -] 0.4
  Control                    11 [+ or -] 1      11 [+ or -] 2
Cstat (mL/mmHg)
  Transfusion                44 [+ or -] 5      49 [+ or -] 8
  Control                    46 [+ or -] 15     43 [+ or -] 9
Airway resistance (mmHg x
  [L.sup.-1] x [s.sup.-1])
  Transfusion                 7 [+ or -] 2       6 [+ or -] 1
  Control                     7 [+ or -] 1       7 [+ or -] 2
Inspiratory energy (%)
  Transfusion                56 [+ or -] 2            --

  Control                    57 [+ or -] 3            --
Expiratory energy (%)
  Transfusion                43 [+ or -] 4            --

  Control                    40 [+ or -] 7            --

Hysteresis energy (%)
  Transfusion                13 [+ or -] 4            --

  Control                    17 [+ or -] 7            --
ETVI (mL/kg)
  Transfusion               6.2 [+ or -] 1     5.4 [+ or -] 1
  Control                     8 [+ or -] 2     7.2 [+ or -] 2.1

Variable                                Resuscitation

                                  1 h                3 h

P/F ratio
  Transfusion               316 [+ or -] 49    288 [+ or -] 69
  Control                   293 [+ or -] 77    268 [+ or -] 65
EtC[O.sub.2] (mmHg)
  Transfusion                35 [+ or -] 3      38 [+ or -] 2

  Control                    37 [+ or -] 5      39 [+ or -] 2
Ppeak (cm[H.sub.2]O)
  Transfusion                22 [+ or -] 4      24 [+ or -] 7
  Control                    24 [+ or -] 4      26 [+ or -] 6
Pplateau (cm[H.sub.2]O)
  Transfusion                17 [+ or -] 3      19 [+ or -] 5
  Control                    18 [+ or -] 2      19 [+ or -] 3
Pmean (cm[H.sub.2]O)
  Transfusion                10 [+ or -] 1      10 [+ or -] 2
  Control                    10 [+ or -] 1      11 [+ or -] 1
Cstat (mL/mmHg)
  Transfusion                46 [+ or -] 10     43 [+ or -] 11
  Control                    41 [+ or -] 8      38 [+ or -] 9
Airway resistance (mmHg x
  [L.sup.-1] x [s.sup.-1])
  Transfusion                 8 [+ or -] 2       8 [+ or -] 2
  Control                     8 [+ or -] 2       9 [+ or -] 3
Inspiratory energy (%)
  Transfusion                56 [+ or -] 2      54 [+ or -] 2

  Control                    57 [+ or -] 2      57 [+ or -] 6
Expiratory energy (%)
  Transfusion                43 [+ or -] 3      41 [+ or -] 2

  Control                    42 [+ or -] 6      36 [+ or -] 4

Hysteresis energy (%)
  Transfusion                13 [+ or -] 3      13 [+ or -] 2
                                                 ([section])
  Control                    15 [+ or -] 5      21 [+ or -] 7
ETVI (mL/kg)
  Transfusion               6.4 [+ or -] 1.2   6.8 [+ or -] 1.6
  Control                   7.8 [+ or -] 2.8     8 [+ or -] 2.6

Variable                      Resuscitation           P value

                                   6 h

P/F ratio
  Transfusion               255 [+ or -] 85 *   <0.001 ([paragraph])
  Control                   247 [+ or -] 73 *    0.055 (&)
EtC[O.sub.2] (mmHg)
  Transfusion                37 [+ or -] 3       0.346 ([paragraph])

  Control                    37 [+ or -] 6       0.022 (&)
Ppeak (cm[H.sub.2]O)
  Transfusion                25 [+ or -] 8       0.105 ([paragraph])
  Control                    26 [+ or -] 5       0.061 (&)
Pplateau (cm[H.sub.2]O)
  Transfusion                20 [+ or -] 6       0.237 ([paragraph])
  Control                    20 [+ or -] 4       0.739 (&)
Pmean (cm[H.sub.2]O)
  Transfusion                11 [+ or -] 3       0.448 ([paragraph])
  Control                    12 [+ or -] 1       0.042 (&)
Cstat (mL/mmHg)
  Transfusion                41 [+ or -] 12      0.040 ([paragraph])
  Control                    37 [+ or -] 9       0.110 (&)
Airway resistance (mmHg x
  [L.sup.-1] x [s.sup.-1])
  Transfusion                 8 [+ or -] 2       0.090 ([paragraph])
  Control                     9 [+ or -] 3       0.287 (&)
Inspiratory energy (%)
  Transfusion                53 [+ or -] 1       0.479 ([paragraph])
                               ([section])
  Control                    57 [+ or -] 5       0.009 (&)
Expiratory energy (%)
  Transfusion                40 [+ or -] 3       0.023 ([paragraph])
                               ([section])
  Control                    35 [+ or -] 4       0.008 (&)
                                 (#)
Hysteresis energy (%)
  Transfusion                13 [+ or -] 3       0.257 ([paragraph])
                               ([section])
  Control                    21 [+ or -] 5      <0.001
ETVI (mL/kg)
  Transfusion               6.5 [+ or -] 0.9     0.557 ([paragraph])
  Control                   7.8 [+ or -] 2.5    <0.001

Data are reported as means [+ or -] SD for 8 animals per group.
Inspiratory energy, expiratory energy and hysteresis energy were
calculated using the pressure x volume (P x V) curve of the
respiratory system normalized to the area of the rectangle enclosing
the P x V curve (29). P/F ratio: Pa[O.sub.2]/Fi[O.sub.2] ratio;
EtC[O.sub.2]: end-tidal carbon dioxide concentration; Ppeak: peak
airway pressure; Pplateau: plateau airway pressure; Pmean: mean
airway pressure; Cstat: respiratory system static compliance; ETVI:
extra-vascular thermal volume index. There is no factor vs time
interaction. ([paragraph]) ANOVA two-way within factor. (&) ANOVA
two-way between factor. * P<0.05 vs baseline, Tukey's post-hoc
analysis. ([section]) P<0.05 vs Control group, Tukey's post-hoc
analysis, (#) P<0.05 vs 1 h resuscitation, Tukey's post- hoc
analysis.
COPYRIGHT 2018 Associacao Brasileira de Divulgacao Cientifica (ABDC)
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Biagini, S.; Dale, C.S.; Real, J.M.; Moreira, E.S.; Carvalho, C.R.R.; Schettino, G.P.P.; Wendel, S.;
Publication:Brazilian Journal of Medical and Biological Research
Article Type:Report
Date:Jan 1, 2018
Words:7497
Previous Article:Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer.
Next Article:Safety and efficacy of regional citrate anticoagulation in continuous blood purification treatment of patients with multiple organ dysfunction...
Topics:

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |